Filters

Pp-233 manufacturers

Filters

None products found

pp-233

Solution for infusion

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Indication: Congenital Myasthenic Syndromes (CMS) / Clinical stage: Phase 3 / Modality: Biologic - first-in-class agonist antibody targeting muscle-specific kinase (MuSK) / Mechanism & Target: MuSK agonist; novel mechanism for CMS / Route & form: IV / Differentiation: First-in-class MuSK agonist; addresses rare neuromuscular disorder
Manufacturer #39439
International biotechnology company focused on rare and severe autoimmune diseases. Develops FcRn-modulating and complement-targeting biologics for neuromuscular and immune-mediated conditions. Advances multiple Phase 3 programs through global clinical development.

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Willing to unlock more features?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.